A protocol for the delivery of cannabidiol (CBD) and combined CBD and ∆9-tetrahydrocannabinol (THC) by vaporisation

[1] D’Souza DC(2004)The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis Neuropsychopharmacology 29 1558-1572

[2] Perry E(2008)Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action Rev Bras Psiquiatria 30 271-280

[3] MacDougall L(2012)Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia Transl Psychiatry 2 e94-307

[4] Ammerman Y(2008)Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis Br J Psychiatry 192 306-290

[5] Cooper T(2010)Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study Br J Psychiatry 197 285-774

[6] Wu YT(2010)Opposite effects of ∆-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology Neuropsychopharmacology 35 764-5014

[7] Braley G(2012)Subjective and physiological effects of oromucosal sprays containing cannabinoids (nabiximols): potentials and limitations for psychosis research Curr Pharm Des 18 5008-363

[8] Gueorguieva R(1983)Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women Clin Pharmacol Ther 34 352-360

[9] Krystal JH(2003)Pharmacokinetics and pharmacodynamics of cannabinoids Clin Pharmacokinetics 42 327-43

[10] Zuardi AW(1986)Pharmacokinetics and metabolism of delta-1-tetrahydrocannabinol and other cannabinoids with emphasis on man Pharmacol Rev 38 21-1317

[1] D’Souza DC(2004)The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis Neuropsychopharmacology 29 1558-1572

[2] Perry E(2008)Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action Rev Bras Psiquiatria 30 271-280

[3] MacDougall L(2012)Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia Transl Psychiatry 2 e94-307

[4] Ammerman Y(2008)Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis Br J Psychiatry 192 306-290

[5] Cooper T(2010)Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study Br J Psychiatry 197 285-774

[6] Wu YT(2010)Opposite effects of ∆-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology Neuropsychopharmacology 35 764-5014

[7] Braley G(2012)Subjective and physiological effects of oromucosal sprays containing cannabinoids (nabiximols): potentials and limitations for psychosis research Curr Pharm Des 18 5008-363

[8] Gueorguieva R(1983)Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women Clin Pharmacol Ther 34 352-360

[9] Krystal JH(2003)Pharmacokinetics and pharmacodynamics of cannabinoids Clin Pharmacokinetics 42 327-43

[10] Zuardi AW(1986)Pharmacokinetics and metabolism of delta-1-tetrahydrocannabinol and other cannabinoids with emphasis on man Pharmacol Rev 38 21-1317